Comparative Pharmacology
Head-to-head clinical analysis: LANIAZID versus PHENY PAS TEBAMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LANIAZID versus PHENY PAS TEBAMIN.
LANIAZID vs PHENY-PAS-TEBAMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isoniazid inhibits the synthesis of mycolic acids, essential components of the mycobacterial cell wall, by targeting the enoyl-acyl carrier protein reductase InhA after activation by the mycobacterial catalase-peroxidase KatG.
Phenyl-PAS-Tebamin is a combination of p-aminosalicylic acid (PAS) and phenyl aminosalicylate. PAS inhibits folic acid synthesis in Mycobacterium tuberculosis by competing with p-aminobenzoic acid (PABA) for the enzyme dihydropteroate synthase, thereby blocking the conversion of PABA to dihydrofolate. The phenyl ester may enhance gastrointestinal absorption and tolerability.
5 mg/kg orally once daily, maximum 300 mg/day; or 300 mg intramuscularly once daily.
8-12 g/day orally in 3-4 divided doses (4 g every 8-12 hours) as p-aminosalicylic acid; administered as granules or tablets.
None Documented
None Documented
Fast acetylators: 0.5-1.5 hours; slow acetylators: 2-5 hours. Clinical context: Accumulation risk in slow acetylators with standard dosing, requiring monitoring for hepatotoxicity and peripheral neuropathy.
Terminal elimination half-life for p-aminosalicylic acid is approximately 0.75-1 hour; for phenyl-p-aminosalicylate, half-life is longer, around 2-3 hours, allowing twice-daily dosing for improved compliance.
Renal: 70-80% as unchanged drug and metabolites (acetylisoniazid, isonicotinic acid); fecal: negligible (approximately 7%)
Renal: 85-90% (mostly as inactive metabolites, with <5% as p-aminosalicylic acid and <1% as phenyl-p-aminosalicylate); Biliary/Fecal: 5-10%.
Category C
Category C
Antitubercular
Antitubercular